Previous Article | Next Article 
Molecular and Cellular Biology, November 1999, p. 7436-7446, Vol. 19, No. 11
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Targeted Disruption of the Murine
fps/fes Proto-Oncogene Reveals that Fps/Fes Kinase Activity
Is Dispensable for Hematopoiesis
Yotis
Senis,1
Ralph
Zirngibl,2
Jennifer
McVeigh,1
Andre
Haman,3
Trang
Hoang,3 and
Peter A.
Greer1,2,*
Department of
Pathology1 and Department of
Biochemistry,2 Cancer Research Laboratories,
Queen's University, Kingston, Ontario K7L 3N6, and Laboratory
of Hemopoiesis and Leukemia, Institut de Recherches Cliniques de
Montreal, Montreal, Quebec H2W 1R7,3 Canada
Received 2 August 1999/Accepted 5 August 1999
 |
ABSTRACT |
The fps/fes proto-oncogene encodes a cytoplasmic
protein-tyrosine kinase that is functionally implicated in the survival
and terminal differentiation of myeloid progenitors and in signaling from several members of the cytokine receptor superfamily. To gain
further insight into the physiological function of fps/fes, we targeted the mouse locus with a kinase-inactivating missense mutation. Mutant Fps/Fes protein was expressed at normal levels in
these mice, but it lacked detectable kinase activity. Homozygous mutant
animals were viable and fertile, and they showed no obvious defects.
Flow cytometry analysis of bone marrow showed no statistically significant differences in the levels of myeloid, erythroid, or B-cell
precursors. Subtle abnormalities observed in mutant mice included
slightly elevated total leukocyte counts and splenomegaly. In bone
marrow hematopoietic progenitor cell colony-forming assays, mutant mice
gave slightly elevated numbers and variable sizes of CFU-granulocyte
macrophage in response to interleukin-3 (IL-3) and
granulocyte-macrophage colony-stimulating factor (GM-CSF). Tyrosine
phosphorylation of Stat3 and Stat5A in bone marrow-derived macrophages
was dramatically reduced in response to GM-CSF but not to IL-3 or IL-6.
This suggests a distinct nonredundant role for Fps/Fes in signaling
from the GM-CSF receptor that does not extend to the closely related
IL-3 receptor. Lipopolysaccharide-induced Erk1/2 activation was also
reduced in mutant macrophages. These subtle molecular phenotypes
suggest a possible nonredundant role for Fps/Fes in myelopoiesis and
immune responses.
 |
INTRODUCTION |
The fps/fes
proto-oncogene (hereafter referred to simply as fps) encodes
a nonreceptor protein-tyrosine kinase (PTK) (2, 55, 62)
which is abundantly expressed in cells of the myeloid lineage (13,
15, 21, 41), where it has been proposed to play an essential role
in regulating survival and terminal differentiation (14,
68). Transfection of the K562 erythroleukemia cell line with
fps potentiated phorbol ester-induced terminal myeloid
differentiation (68), while fps antisense
oligonucleotides blocked retinoic acid-induced granulocytic
differentiation and led to apoptosis in acute promyelocytic leukemia
cells (14). Although fps displays a limited
tissue-specific expression pattern, the biological function of Fps
cannot be restricted to a role in myelopoiesis, as it is also expressed
in several other diverse cell lineages, including endothelial,
epithelial, and neuronal cells (5, 22). In contrast, the
closely related Fer kinase displays a widespread expression pattern
(16, 23, 39). It is possible that, as the only two known
members of this distinct subclass of PTKs, Fps and Fer perform redundant biochemical functions.
In addition to their carboxyl-terminal catalytic domains, Fps and Fer
also contain central SH2 domains and long amino-terminal domains that
include three putative coiled-coil motifs. The amino-terminal domains
mediate homotypic oligomerization of Fps (52) and Fer (8, 35); however, heterotypic oligomers are not formed
between Fps and Fer, and homotypic oligomerization is not required for Fer kinase activation (8). The SH2 domain may regulate Fps activity through intramolecular interactions (28, 36) or
through intermolecular interactions with other tyrosine-phosphorylated proteins, including putative substrates (33). A
phosphopeptide library screen using the Fps SH2 domain as an affinity
matrix has identified a consensus-binding sequence (pYExV/I) which is present in several potential targets, including a number of other protein kinases, tyrosine phosphatases, cell surface antigens, Bcr, and
-adaptin (58).
Oncogenic fps alleles were frequently isolated from avian
(v-fps) and feline (v-fes) retroviruses. These
encode Gag-Fps fusions proteins with unregulated kinase activities
which can abrogate cytokine requirements and influence differentiation
of hematopoietic progenitor cells (6, 34, 35) and reduce or
eliminate growth factor requirements in transformed fibroblasts
(56). Interestingly, Fps activation in fibroblasts
correlated with down-regulation of the platelet derived growth factor
-chain (PDGF
) receptor (3). Expression of Gag-Fps
proteins in transgenic mice under the control of a minimal
-globin
promoter caused tumors in lymphoid and mesenchymal tissues
(66) and hypertrophic effects in the heart and trigeminal
nerves (67). In contrast, tissue-specific overexpression of
wild-type cellular fps in transgenic mice caused no overt
phenotype (21), while mice expressing low levels of an
activated fps allele developed vascular hyperplasia
progressing to multifocal hemangiomas but exhibited no apparent
hematopoietic defects or malignancies (20).
Increased tyrosine phosphorylation has been described for a number of
cellular proteins in v-fps-transformed fibroblast cells, including Ras-specific GTPase-activating protein (Ras-GAP) and the
associated Rho-GAP and Dok proteins (12, 36, 46), Bcr (42), Shc (44), phosphatidylinositol 3'-kinase
(17), the SH2-containing signal transducers and activators
of transcription [Stat]) protein Stat3 (18), the PDGF
receptor (3), and connexin 43 (37). Putative
substrates for the cellular Fps kinase include Bcr and Ras-GAP
(27, 42), Stat3 (48), and Cas and Fyb (9, 33).
Potential molecular roles for cellular Fps have largely focused on
signaling downstream from cytokine receptor superfamily members,
including those for granulocyte-macrophage colony-stimulating factor
(GM-CSF), interleukin 3 (IL-3), IL-4, IL-6, and IL-11, erythropoietin
(Epo) oncostatin M, leukemia inhibitory factor, and ciliary
neurotrophic factor. Fps or a closely related kinase becomes tyrosine
phosphorylated upon stimulation of responsive cells with IL-3
(24), GM-CSF (24, 40), IL-4 (32), IL-6 (43), and Epo (25). Fps has also been detected in
association with a number of cytokine receptors, including those for
IL-4 (32), the shared
-chain of the human IL-3, IL-5, and
GM-CSF receptors (4, 24, 51), as well as the common gp130
chain which is used by the receptors for IL-6, IL-11, leukemia
inhibitory factor, oncostatin M, and ciliary neurotropic factor
(43). Interestingly, overexpression of catalytically
inactive Fps in cytokine-dependent TF-1 or 32D cells did not interfere
with proliferative responses to GM-CSF and IL-3 or differentiation in
response to G-CSF (64).
Despite evidence of cytokine-induced activation of Fps and association
with cytokine receptors, its involvement in cytokine receptor signaling
remains unclear. This is in contrast to more established roles for
nonreceptor PTKs of the Jak (Janus), Syk, and Src families (7, 30,
38). To further explore the in vivo function of the Fps kinase
and clarify its role in cytokine signaling and myelopoiesis, we have
targeted the endogenous mouse fps locus with a
kinase-inactivating missense mutation. We show that mice expressing
only inactive Fps display normal levels of hematopoietic cell types in
the periphery and bone marrow (BM); this demonstrates that Fps activity
is not required for normal hematopoiesis. BM from these mice contain
normal numbers of hematopoietic progenitors of the myeloid, erythroid,
and lymphoid lineages, and BM-derived myeloid progenitor cells display
normal colony-forming responses to a number of cytokines, including
IL-3 and GM-CSF. Therefore, either Fps kinase activity is not involved
in the cellular response to these cytokines, or the biochemical
function that it provides is redundant. Interestingly, BM macrophages
(BMM) from mutant mice displayed dramatically reduced tyrosine
phosphorylation of Stat3 and Stat5A in response to GM-CSF but not IL-3.
We also noticed a dose-dependent reduction in lipopolysaccharide
(LPS)-induced tyrosine phosphorylation of Erk1 and Erk2 in BMMs,
suggesting that Fps either plays a direct role in signaling downstream
from the LPS receptor (CD14) or possibly has an indirect effect
resulting from autocrine signaling caused by LPS-induced cytokine
release. These subtle molecular phenotypes suggest a potential
nonredundant role of Fps kinase activity in myeloid cell functions.
 |
MATERIALS AND METHODS |
Construction of the fps gene targeting vector.
The complete murine fps locus has been cloned and sequenced
(unpublished data). PCR mutagenesis using Pfu thermal stable DNA polymerase (Stratagene) was used to convert the AAG codon for Fps
residue lysine 588 to an AGA arginine codon. The template was a 2.5-kbp
genomic XbaI fragment containing exon 14 cloned in pGEM-1
(Promega). PCRs were performed with a sense-strand mutagenic oligonucleotide (5'-GTG GCT GTG AGA TCT TGC CGA-3') in combination with
the T7 primer or an antisense mutagenic oligo (5'-TCG GCA AGA TCT CAC
AGC CAC-3') in combination with the reverse primer. Aliquots of these
two purified PCR products were combined in a second PCR using only the
external T7 and reverse primers. The resulting PCR product was digested
with XbaI and subcloned in place of the corresponding
wild-type XbaI fragment in the context of a plasmid
containing the complete murine fps locus (pXNK4), giving the
mutant version (pXNR24). The mutation was confirmed by DNA sequencing.
The targeting construct was produced in the context of a modified
version of pPNT (61), called pPNT-NHS14, in which the cloning site upstream of the phosphoglycerine kinase (PGK)-neomycin phosphotransferase (neo) cassette was modified by digestion with XhoI and insertion of a linker containing SalI,
HpaI, and NheI sites (unpublished data). A 450-bp
EcoRI fragment located downstream of the last fps
exon was first cloned into the EcoRI site of pPNT-NHS14 between the PGK-neo and PGK-tk (thymidine kinase) cassettes, giving pPNT450HNS14.2. The 9.0-kbp EcoRI fragment from pXNR24 was
subcloned into pBluescriptIIKS
, recovered as a
NotI-to-SalI fragment, and cloned between the
corresponding sites in pPNT450NHS14.2, giving the final targeting vector.
ES cell culture and chimeric mouse production.
Mouse
embryonic stem (ES) cells (R1; passage 8) were kindly provided by
Andras Nagy (47). Propagation, electroporation, and
selection of recombinant R1 clones were carried out essentially as
described by Wurst and Joyner (63) except that the
concentration of 2-mercaptoethanol in culture medium was 100 µM, and
recombinant leukemia inhibitory factor was prepared in bacteria by
using plasmid pGEX-2T-MLIF, kindly provided by L. Grey and J. Heath (54). R1 cells were expanded on embryonic fibroblast
feeder layers; after trypsinization and preplating to remove embryonic
fibroblasts, they were electroporated with the
NotI-linearized targeting vector, using a Gene Pulser
(Bio-Rad). Cells were then plated on gelatinized tissue culture plates
in the absence of embryonic fibroblasts and selected by using 200 µg
of active Geneticin (G418; GibcoBRL) per ml and 2 µM ganciclovir
(Syntex Inc.). Drug-resistant clones were picked and replated onto
gelatinized 24-well plates. After 2 days in culture, the clones were
trypsinized, and 10% was taken for pooled PCR analysis, 80% was
plated onto embryonic fibroblast feeders on 24-well plates, and the
remaining 10% was maintained on gelatinized 24-well plates for
subsequent PCR analysis of individual clones. PCR analysis
(63) was carried out with a sense primer (p2/neo21;
5'-CCGCTTCCTCGTGCTTTACGG-3'), corresponding to sequences in
the 3' region of the PGK-neo cassette, and an antisense primer (p1/mfes1.6RC#2; 5'-GACAGGGTTTCCTGTCATGTG-3'), corresponding
to genomic sequences immediately downstream from the 450-bp
EcoRI fragment used as the short arm of homology. Southern
blot analysis was carried out with the cloned 450-bp EcoRI
fragment as a probe to confirm the identity of ethidium bromide-stained
PCR products. Individual clones from positive pools were analyzed by
the method described above. These clones were expanded on embryonic
fibroblasts, and chimeric mice were produced by the "darning
needle" method (47). Chimeric males were bred with albino
CD1 females, and the fps genotype of agouti pups was
determined by PCR or genomic Southern blotting analysis. Routine
analysis of genotypes was carried out with total DNA from tail biopsy
as templates in PCRs with an exon 13 sense primer (p3;
5'-GACAAGTGGGTTCTGAAGCACGAGG-3') and an exon 15 antisense
primer (p4; 5'-GACCCCGATGAGACGCACAATGTTGG-3'). The PCR
product was subsequently digested with BglII and resolved on
1.2% agarose gels. Ethidium bromide staining revealed a single 1,028-bp PCR product from wild-type animals, 628- and 400-bp fragments from homozygous mutants, and equal molar amounts of all three fragments
from heterozygous mice. Alternatively, genotypes were determined by
Southern blotting analysis of BglII-digested DNA probed with
a complete murine fps cDNA provided by Andrew Wilks (62).
Immune-complex kinase assays and immunoblotting analysis.
BM
was recovered from dissected femurs as previously described
(60). Cos-1 cells were transfected with Fps expression
plasmids by using Lipofectamine reagent as instructed by the
manufacturer (Life Technologies, Inc.). Cells were lysed into 0.7 ml of
KLB (20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM EDTA, 1% [vol/vol] Nonidet P-40, 0.5% [vol/vol] sodium deoxycholic acid, 10 µg of aprotinin per ml, 10 µg of leupeptin per ml, 100 µM sodium
orthovanadate, 100 µM phenylmethylsulfonyl fluoride). Cell lysates
were clarified by centrifugation at 14,000 × g for 20 min at 4°C. Aliquots of 0.1 ml were taken for immunoblotting analysis
of soluble Fps proteins. The remaining 0.6 ml of lysate was added to 20 µl of 30% (vol/vol) protein A conjugated to Sepharose CL-4B and 5 µl of crude polyclonal rabbit antiserum (anti-Fps/Fer, also known as
anti-FpsQE, or anti-FerLA [22]) or 2 µg of an
affinity-purified anti-Fps antibody, which was raised against a TrpE
fusion with human Fps amino acids L401 to Q446 and affinity purified
against a glutathione S-transferase fusion of murine Fps
amino acids Q381 to E563. After mixing on a nutator platform for 2 h at 4°C, immune complexes were collected by brief centrifugation and
then washed five times with KLB and once with KRB (20 mM Tris-HCl [pH
7.5], 10 mM MnCl2, 100 µM sodium orthovanadate). Kinase
reactions were performed by resuspending the washed immune complex with
30 µl of KRB supplemented with 10 µCi of [
-32P]ATP
and incubating the mixture for 20 min at 30°C. Reactions were
terminated by addition of 30 µl of 2× sodium dodecyl sulfate (SDS)
sample buffer and heating at 100°C for 5 min. Proteins were resolved
on SDS-polyacrylamide gels and either dried and subjected to
radioautography for detection of kinase activity or transferred to
Immobilon-P membrane (Millipore) by using a semidry apparatus (Bio-Rad)
for immunoblotting analysis. Membranes were blocked overnight at 4°C
with BLOTTO (5% Carnation skim milk powder in 10 mM Tris-HCl [pH
7.5]-150 mM NaCl). Fps proteins were detected by incubation at room
temperature (RT) for 2 h with 1/500 dilutions of rabbit polyclonal
anti-FpsQE antibody or affinity-purified anti-Fps antibody. After
washing with TBST (10 mM Tris-HCl [pH 7.5], 150 mM NaCl, 0.05%
[vol/vol] Tween 20), membranes were incubated with a 1/10,000
dilution of horseradish peroxidase-conjugated goat anti-rabbit
immunoglobulin G (Vector Laboratories) in TBST for 1 h at RT.
After a wash with TBST, immune complexes were detected by using
enhanced chemiluminescence (ECL) reagents (NEN Life Science Products).
Peripheral blood cell counts.
Mice between 8 and 20 weeks of
age were deeply anesthetized with chloroform, their chest cavities were
opened, and peripheral blood (PB) was collected by cardiac puncture,
using a 1-ml syringe fitted with a 23-gauge needle. Following PB
collection, the blood was quickly mixed with 10% (wt/vol) EDTA
disodium salt to a final concentration of 1.5 ± 0.25 mg of
EDTA/ml of blood to inhibit clotting. Samples were collected at the
same time each day to avoid any differences in cell counts due to the
circadian rhythm of the mice (1). Leukocyte (WBC) counts,
erythrocyte counts, hemoglobin, hematocrit, mean corpuscular volume,
mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration,
and platelet counts were measured in a Baker System 9000 Hematology
Series Cell Counter (Baker Instruments Corporation, Allentown, Pa.). Neutrophil, lymphocyte, monocyte, eosinophil, and basophil levels were
quantified with a CELL-DYN 3500 multiparameter hematology analyzer
(Abbott Diagnostics, Santa Clara, Calif.).
Isolation of BM for colony assays.
Mice between 8 and 16 weeks of age were euthanized by cervical dislocation, and femurs were
dissected free of muscle and connective tissue by aseptic technique.
Posterior ends of the femurs were cut open to expose the BM, which was
flushed into 5 ml of ice-cold macrophage starvation media consisting of
Dulbecco modified Eagle medium (GibcoBRL Life Technologies Inc., Grand
Island, N.Y.), 0.5% fetal calf serum FCS; HyClone, Logan, Utah), 50 µM
-monothioglycerol (Sigma), and 1% antibiotic-antimycotic
(GibcoBRL Life Technologies), using a 5-ml syringe fitted with a
23-gauge needle. Large clumps of marrow were disrupted by gently
passing the freshly flushed BM through the needle several times. Cell
counts were performed in a Coulter ZBI cell counter (Coulter
Electronics Inc., Hialeah, Fla.).
Hematopoietic progenitor cell colony-forming assay.
Methylcellulose clonal cultures were established to assess the levels
of hematopoietic progenitor cells in the BM of mice. Briefly, 50,000 unfractionated BM cells were cultured in 1.2 ml of semisolid medium
consisting of 1% methylcellulose (Fluka), 10% fetal bovine serum
(FBS), 2% bovine serum albumin (BSA), 200 µg of human plasma
transferrin (iron saturated; (Calbiochem) per ml, 50 µM
-monothioglycerol (Sigma), and either (i) a cytokine cocktail
consisting of recombinant human Epo (1 U/ml; R&D Systems), recombinant
murine IL-3 (5 ng/ml; (R&D Systems), recombinant murine Steel factor
(SF) (50 ng/ml; R&D Systems), and recombinant murine IL-6 (10 ng/ml;
R&D Systems); (ii) recombinant murine GM-CSF (5 ng/ml; R&D Systems) and
recombinant human Epo (1 U/ml); or (iii) recombinant human Epo (1 U/ml)
alone. All BM samples were cultured in duplicate at 37°C and 5%
CO2 in a humidified atmosphere. Colony counts were made by
placing each 35-mm-diameter plate within a gridded 60-mm-diameter
tissue culture plate, and the entire area was scored with a Leitz
Labovert inverted microscope (Leitz Wetzlar, Wetzlar, Germany). Plates
were scored as follows: CFU-erythroid (CFU-E) colonies consisting of
one or two clusters of 4 to 32 hemoglobinized erythroblasts per cluster
were counted 2 days postplating; burst-forming unit-erythroid (BFU-E)
colonies consisting of three or more clusters of hemoglobinized
erythroblasts, CFU-macrophage (CFU-M) colonies consisting of 50 or more
cells, CFU-granulocyte-macrophage (CFU-GM) colonies consisting of
50 or more cells, and
CFU-granulocyte-erythroid-macrophage-megakaryocyte (CFU-GEMM)
colonies consisting of 50 or more erythroid, granulopoietic, and
thrombopoietic cells combined were counted 8 days postplating.
The number of cells per CFU-GM colony were counted by randomly picking
20 colonies from a 1.2-ml methycellulose culture seeded
with 50,000 nucleated BM cells 9 days postplating. Colonies were
picked by using a
P-200 pipetteman and combined in 1 ml of Iscove
modified Dulbecco
medium-(IMDM)-2% FBS. Samples were stained with
ethidium
bromide-acridine orange stain and counted with a hemacytometer
on a
light microscope under UV
light.
BMM cultures.
The procedure used for culturing BMM was for
the most part the same as that outlined by Tushinski et al.
(60), with a few minor modifications. BM cells flushed from
femurs of mice were seeded into tissue culture plates (Sarstedt) in
complete macrophage medium consisting of IMDM, 20% L-cell conditioned
medium, 15% FCS, 20 mM glutamine, 1% antibiotic-antimycotic, and 50 µM
-monothioglycerol at a concentration of 106
cells/ml and a density of 2.9 × 105
cells/cm2. Following a 24-h incubation, nonadherent cells
were collected, pelleted at 700 × g for 5 min at RT,
resuspended in half the original volume of complete macrophage medium,
and seeded into fresh tissue culture plates. Adherent cells were
discarded. Following a 2-day incubation, the adherent cells were
discarded, the nonadherent cells were collected and plated in
35-mm-diameter tissue culture plates at a density of 1.9 × 104 cells/cm2 and a concentration of 2 × 105 cells/ml. Following a 3- to 6-day incubation, the
medium was replaced with fresh complete macrophage medium and the
adherent macrophages were allowed to grow to 80 to 90% confluency
before use in any experiments.
Cytokine stimulation of BMM cultures.
BMM cultures were
incubated in macrophage starvation medium for 24 h, which was then
replaced with fresh macrophage starvation medium for an additional
24 h prior to exposure of the cells to any cytokines. On the day
of the experiment, macrophages were rinsed once with prewarmed
phosphate-buffered saline (PBS) and then incubated in IMDM for 2 h. After a rinse with prewarmed IMDM, the cells were incubated with
either 30 ng of recombinant murine GM-CSF, IL-3, or IL-6 (all from R&D
Systems) per ml diluted in prewarmed IMDM at 37°C for 15 min. In the
case of stimulation with LPS from Escherichia coli serotype
O55:B5 (Sigma), cells were incubated with either 10, 100, or 1,000 ng
of LPS per ml in prewarmed IMDM at 37°C for 30 min. Plates were put
on ice immediately following exposure to the various treatments, the
medium was quickly aspirated, and plates were rinsed with ice-cold PBS
containing 100 µM sodium orthovanadate. Cell lysates from
35-mm-diameter tissue culture plates were scraped into 200 µl of 2×
SDS protein sample buffer by using a rubber policeman, passed through a
P-200 pipette tip several times to shear high-molecular-weight DNA, heated to 100°C for 10 min, centrifuged briefly at 14,000 × g, and then either run out on an SDS-7.5 or 11%
polyacrylamide protein gel or stored at
20°C. Proteins were
transferred by semidry blotting to Immobilon-P membrane, blocked with
either 5% BSA TBST, 5% milk powder in TBST, or 3% milk powder in PBS
and probed with the following antibodies: rabbit anti-rat Erk (clone
K-23; Santa Cruz), mouse anti-human phospho-ERK (pErk (clone E-4; Santa
Cruz), rabbit anti-mouse Stat3 (New England Biolabs), mouse anti-human
pStat3 (clone 9E12; Upstate Biotechnology), rabbit anti-human Stat5A
(Upstate Biotechnology), mouse anti-human pStat5A/B (clone 8-5 2;
Upstate Biotechnology), rabbit anti-mouse Jak2 (Upstate Biotechnology),
and rabbit anti-pJak2 (QCB Biosciences International). The secondary
antibody used to detect the proteins was either peroxidase-conjugated
goat anti-rabbit (Boehringer Mannheim) or peroxidase-conjugated sheep
anti-mouse (Amersham Life Sciences), depending on the primary antibody
used. Membranes were then exposed to ECL reagents (NEN Life Science Products) and then to film.
Flow cytometry.
Single-cell suspensions of BM cells were
isolated from mouse femurs as described above; BM was flushed into PBS
(pH 7.4) containing EDTA (1.5 mg/ml) at RT. Following extraction, BM
cells were centrifuged at 300 × g for 5 min at RT and
resuspended at a concentration of 20 × 106 cells/ml
in PBS-0.5% BSA-0.1% sodium azide (pH 7.2) (PAB). For staining of
lineage-specific surface antigens, 2 × 106 cells in
100 µl of PAB were initially incubated with rat anti-mouse CD16/CD32
(PharMingen Canada, Mississauga, Ontario, Canada) for 5 min at 4°C,
to block Fc II and Fc III receptors. Cells were then incubated for 15 min at 4°C with the following monoclonal antibodies (MAbs) diluted in
10 µl of PAB: phycoerythrin (PE)-conjugated rat anti-mouse Ly-6G,
fluorescein isothiocyanate (FITC)-conjugated rat anti-mouse CD11b,
PE-conjugated rat anti-mouse TER-119, FITC-conjugated rat anti-mouse
CD44, and PE-conjugated rat anti-mouse CD45R/B220 (all purchased from
PharMingen Canada).
Erythrocytes were lysed by adding 2 ml of ice-cold lysis buffer (154 mM
ammonium chloride, 10 mM potassium bicarbonate, 100
µM EDTA disodium
salt) and incubated for 5 min at 4°C with constant
motion. Samples
were then centrifuged at 300 ×
g for 5 min at
RT,
washed once with 4 ml of PAB, and resuspended in 1 ml of 1%
paraformaldehyde in cacodylate buffer (pH 7.2) for analysis on
the flow
cytometer.
Statistical analysis.
The means and standard deviations (SD)
of all numeric data were calculated. Data were analyzed by Student's
t test, where appropriate. Comparisons of data sets yielding
P values of greater than 0.05 were regarded as not
statistically different.
 |
RESULTS |
Targeting of the murine fps gene.
To investigate
the in vivo function of the fps proto-oncogene, gene
targeting was used to generate transgenic mice expressing catalytically
inactive Fps from the endogenous loci. The targeting vector (Fig.
1) consisted of (i) the Neo positive
selectable marker flanked by a 450-bp short arm of homology
corresponding to sequences in the 3' flanking region of the
fps locus and (ii) a 9-kbp long arm of homology containing
exons 4 through 19 of fps. The herpes simplex virus
thymidine kinase gene was included downstream of the short arm of
homology to provide negative selection for nonhomologous recombination
events. A dinucleotide mutation was introduced into exon 14, which is
located midway through the long arm of homology. This mutation
generated a novel BglII site and converted the lysine 588 codon to an arginine codon. Lysine 588 corresponds to a completely conserved residue in the protein kinase family which is located in
kinase subdomain II and is known to be essential for catalytic function. We also engineered a cDNA version of this mutation in a human
fps expression plasmid and showed that the encoded kinase lacked detectable catalytic activity in transfected Cos-1 cells (see
Fig. 3A).

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 1.
Structure of the murine fps locus and
targeting strategy. The top line illustrates a restriction map of the
murine fps locus; the 19 exons are indicated by black
rectangles, and the promoter is indicated with a horizontal arrow. The
targeting vector is shown on the middle line, with the two arms of
homology from the 9- and 0.45-kbp EcoRI fragments shown as
thick lines on either side of the PGK-neo cassette. The position of the
mutation and novel BglII site in exon 14 is indicated with a
vertical arrow. The PGK-tk cassette and flanking vector sequences are
located to the right of the short arm of homology. The intersecting
dotted lines indicate the presumptive regions of homologous
recombination leading to the targeted locus shown on the bottom line.
The positions of primers used for PCR screening (p1,p2) and analysis of
genotypes (p3,p4) are indicated with arrowheads. The lengths of
BglII fragments are indicated below the targeted locus.
Restriction sites for BglII, EcoRI, and
XbaI are indicated as Bg, R, and X, respectively. The
polymorphic BglII site located in the 5' flanking region is
indicated in parentheses.
|
|
The linearized targeting vector was electroporated into the R1 murine
ES cell line (
47), and combined G418-gancyclovir selection
was applied. A total of 647 clones were screened by PCR across
the
short arm of homology, using primers p1 and p2 (Fig.
1). We
identified
14 PCR-positive clones, which corresponded to a targeting
frequency of
approximately 2%. Homologous recombination could
have occurred either
upstream or downstream from the engineered
mutation in the long arm of
homology. We therefore performed a
genomic Southern blotting analysis
of
BglII-digested ES cell DNA
and determined that 7 of 14 targeted ES cell clones had incorporated
the novel
BglII
site (data not shown). Three of these cell lines
were used to produce
chimeric mice by using the darning needle
aggregation method
(
47), and germ line transmission of the
fpsK588R allele was established. No obvious
phenotype was apparent in
heterozygous mutant mice, and when these were
interbred, wild
type, heterozygous, and homozygous mutant mice were
produced in
the expected Mendelian ratios (Table
1). Furthermore, homozygous
mutant males
and females were both fertile. Genotypes were routinely
determined by
PCR amplification of an exon 14-containing genomic
sequence, using
primers p3 and p4 (Fig.
1), followed by digestion
with
BglII
(Fig.
2B). Alternatively, genotypes were determined
by Southern
blotting analysis of total genomic DNA digested with
BglII
and probed with the complete
fps cDNA (Fig.
2A). A 6.8-kbp
fragment encompassing most
of the gene is reduced to 4.8- and
2.0-kbp fragments in the targeted
allele. However, this analysis
was complicated by the existence of an
additional
BglII polymorphism
in the 5' flanking region of
the
fps locus. The
BglII site shown
in
parentheses in Fig.
1 is present in the 129/Sv but not the
129/SvJ
genetic background. Therefore, depending on which alleles
are present,
the 5' end of the locus appears on
BglII fragments
of either
2.1 kbp or approximately 10 kbp. This polymorphism was
confirmed by
probing
BglII-digested DNA from 129/Sv and 129/SvJ
mice with
the cloned 2.1-kbp
BglII fragment (data not shown).
The R1
ES cell line used in these experiments was derived from
(129/Sv × 129/SvJ)F
1 hybrid embryos, while the genomic library
used
to clone
fps was prepared from 129/Sv DNA. Interestingly,
although the targeting vector was produced from the cloned 129/Sv
gene,
which has this 5'
BglII site, the 129/SvJ allele was
targeted
in the ES cell clone used to establish these mice.

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 2.
Genotype analysis by Southern blotting and PCR. (A)
Southern blot analysis of BglII-digested genomic DNA from
animals that are wild type (wt) or either heterozygous (het) or
homozygous (hom) for the mutant fpsK588R allele.
Hybridization with a complete cDNA probe detected BglII
fragments of 2.4 and 1.6 kbp in all samples, while the 6.8-kbp fragment
in the wild-type allele is reduced to 4.8- and 2.0-kbp BglII
fragments in the mutant allele. Two additional fragments of 2.1 or
approximately 10 kbp are diagnostic of a polymorphic BglII
site in the fps 5' flanking region (Fig. 1). (B) PCR
products from mouse genomic DNA using primers p3 and p4, which flank
the mutation point (Fig. 1). The 1,028-bp PCR product is seen in all
samples before BglII digestion ( ), and this is partially
or completely reduced by BglII digestion (+) to 628 and 400 bp in samples which are heterozygous or homozygous for the mutant
allele, respectively.
|
|
Mice homozygous for the fpsK588R allele
express inactive Fps.
We next examined Fps expression and kinase
activity in BM, which is the major myeloid compartment. Fps was
immunoprecipitated from isolated BM cells, and immune-complex kinase
assays were performed to assess the intrinsic autophosphorylation
activity. Although animals from all three genotypes expressed equal
amounts of Fps protein, kinase activity was not detected in the
homozygous mutant animals, and reduced activity was clearly apparent in
the heterozygous mutant animals (Fig.
3B). We next examined BM for expression
of the Fps-related kinase, Fer. Immune-complex kinase assays were
repeated with an antibody which is cross-reactive for Fps and Fer in
parallel with an antibody specific for Fer. This analysis showed that
the slower-migrating Fer kinase was present in all three genotypes,
while the faster-migrating Fps kinase displayed reduced activity
relative to Fer in the heterozygous mutant animals and was completely
inactive in the homozygous mutant animals (Fig. 3C). In several
independent experiments of this type, we were unable to find evidence
for changes in Fer expression or kinase activity in BM from the mutant
animals.

View larger version (51K):
[in this window]
[in a new window]
|
FIG. 3.
Analysis of Fps expression and kinase activity. (A)
Lysates from Cos-1 cells (control) or Cos-1 cells transfected with cDNA
expression plasmids encoding either wild type (Fps) or mutant
(FpsK588R) proteins or empty vector (control) were subjected to
immune-complex kinase assays (top) and immunoblotting (bottom). (B)
Similar analysis of BM from wild-type (wt) animals or mice which were
heterozygous (het) or homozygous (hom) for the
fpsK588R allele. (C) Immune-complex kinase assay
of bone marrow from animals of the three genotypes, using an antibody
either specific for the related Fer kinase ( -Fer) or cross-reactive
for Fps and Fer ( -Fps/Fer). The positions of p94 Fer and p92 Fps are
indicated.
|
|
Viability and fertility of mice expressing catalytically inactive
Fps.
Of the 485 pups born to 20 different heterozygous × heterozygous breeding pairs, 112 (23%) were wild type, 272 (56%) were heterozygous for the fpsK588R allele, and 101 (21%) were homozygous for the mutant fpsK588R
allele (Table 1). This clearly demonstrated that Fps kinase activity
was not required for development or maturation. Furthermore, similar
percentages of the three possible genotypes were seen in male and
female offspring, indicating that the absence of Fps activity did not
compromise the development of either gender. These results suggest that
catalytically active Fps is not required for normal mouse development.
Mice heterozygous or homozygous for the
fpsK588R
allele appeared healthy, developed normally and did not display any
impairment
of reproductive capacity and neonatal survival. Both
heterozygous
× heterozygous and homozygous × homozygous
breeding pairs produced
litters similar in size to those produced by
wild type × wild
type breeding pairs (Table
2), demonstrating that catalytically
inactive Fps does not hinder the fertility of male or female mice.
Hematologic analysis of PB.
PB was collected from mice of all
three genotypes and analyzed for hematologic abnormalities. Both male
and female mice between 8 and 20 weeks of age were included in this
study. Mice were excluded if they had either previously been set up in
a breeding pair or were clearly injured due to fighting with other
mice, both of which may have skewed the data due to physiologic changes
associated with pregnancy or trauma. Despite high levels of Fps
expression in cells of the myeloid/monocytic lineage (13, 15, 21,
41) and in vitro evidence suggesting that Fps plays a role in
myeloid cell differentiation (14, 65, 68), no statistically
significant differences were found between wild-type and homozygous
mutant mice in the levels of any of the hematopoietic cell types
quantified in the peripheral circulation of these mice (Table
3). All 14 of the hematologic parameters
measured were within published normal ranges for laboratory mice of
various strains (57). Substantial intermouse variability was
observed in total WBC and levels of neutrophils, lymphocytes,
monocytes, eosinophils, and basophils in mice of all three genotypes,
which may have masked any subtle differences between the genotypes.
Spleen weights.
Spleens were removed from mice following PB
collection and weighed as an indicator of possible changes in the
physiologic functions of this organ. A skewing toward heavier spleens
was seen in heterozygous and homozygous mutant mice compared with wild-type mice (Fig. 4), and broader
ranges in spleen weights were seen for both homozygous and heterozygous
mutant animals. However, a P value of 0.057 was calculated
by Student t test, which indicated that the observed
differences in weights are not statistically significant. Histological
analysis did not reveal any substantial differences in cellularity or
morphology in the spleen or other tissues.

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 4.
Spleen weights. Normalized spleen weights of wild-type
(wt) mice (n = 35) and animals either heterozygous
(het; n = 79) or homozygous (hom; n = 55) for the fpsK588R allele. Spleen weights
are presented as percentages of body weight. The dots below and above
each box plot represent the 5th and 95th percentiles, respectively. The
whiskers below and above each box plot extend to the 10th and 90th
percentiles, respectively. Each box extends from the 25th to the 75th
percentiles; the solid line within each box represents the median, and
the dashed line represents the mean. Mean normalized spleen weight
percentages ± SD): wt, 0.30% ± 0.08%; het, 0.36% ± 0.21%;
hom, 0.39% ± 0.27%. Means of actual spleen weights ± SD
(range) wt, 107 ± 28 mg (54 to 181 mg); het, 132 ± 76 mg
(57 to 639 mg); hom, 133 ± 96 mg (85 to 780 mg). Comparison of wt
versus hom data sets of normalized spleen weights by Student's
t test yielded a P value of 0.057.
|
|
BM hematopoietic progenitors.
Hematopoietic progenitors were
cultured ex vivo in semisolid methylcellulose medium in the presence of
either a cytokine cocktail (consisting of IL-3, IL-6, SF, and Epo) as a
positive control, GM-CSF and Epo, or Epo alone. We observed no
statistically significant differences in the numbers, types, or
morphologies of the resulting hematopoietic colonies from mice of the
different fps genotypes under any of these conditions (Fig.
5A to C). However, elevated numbers of
CFU-GM-derived colonies and larger colony sizes were occasionally
observed with some homozygous mutant mice in the presence of GM-CSF and
Epo. Consequently, we analyzed the cellularity of CFU-GM colonies by
randomly picking 20 colonies from each plate, pooling the cells, and
counting them as an indicator of the proliferative capacity of the
fps mutant CFU-GM progenitors relative to the wild-type
progenitors (Fig. 5D). However, this did not reveal any statistically
significant differences. Other stimuli tested included GM-CSF alone,
IL-3 alone, M-CSF alone, or IL-3 with Epo, none of which revealed any
significant differences (data not shown). These results demonstrate
that catalytically active Fps tyrosine kinase is not necessary for BM
hematopoietic progenitor cells to proliferate and differentiate in
response to stimulation with either a cytokine cocktail, GM-CSF and
Epo, IL-3 and Epo, Epo alone, or M-CSF alone.

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 5.
BM hematopoietic progenitor cell colony assays. (A) BM
cells were grown in the presence of a cocktail of cytokines, consisting
of IL-3 (5 ng/ml), IL-6 (10 ng/ml), SF (50 ng/ml), and Epo (1 U/ml).
(B) BM cells were grown in the presence of GM-CSF (5 ng/ml) and Epo (1 U/ml). Bars in panels A and B: white, total number of colonies;
hatched, CFU-GM and CFU-M colonies combined; stippled, BFU-E colonies;
black, CFU-GEMM colonies. Colony counts were made on day 8 postplating.
In panel C, CFU-E colonies were grown from BM cells under the following
conditions: the cytokine cocktail (white bars), GM-CSF and Epo (hatched
bars), and Epo alone (black bars). CFU-E colony counts were made 2 days
postplating. The sample sizes were six mice per genotype for each
panel. The height of each bar represents the average number of colonies
for the six mice analyzed, and the error bars represent SD. In panel D,
20 CFU-GM colonies were randomly picked from 1.2-ml methylcellulose
cultures which had been seeded with 50,000 nucleated BM cells. Colonies
were picked 9 days postplating, and cells were pooled and counted. The
height of each bar represents the average number of cells per CFU-GM
colony, and error bars indicate SD. The sample sizes were four mice of
each genotype.
|
|
Flow cytometry analysis of BM hematopoietic cells.
Flow
cytometry was used to determine whether myelopoiesis, erythropoiesis,
and B-cell precursor production and/or development were in any way
impaired in the BM of mice lacking catalytically active Fps. No
significant differences were observed between mice of the different
fps genotypes in the levels of Ly-6G+
CD11b+ myeloid cells (wild type, 49.7%; heterozygous
mutants, 47.4%; homozygous mutants, 51.4%), TER-119+,
CD44lo erythroid precursors after the CFU-E stage (wild
type, 17.8%; heterozygous mutants, 14.9%; homozygous mutants,
18.1%), or B220+ B-cell precursors (wild type, 30.4%;
heterozygous mutants, 32.5%; homozygous mutants, 26.0%) (Fig.
6). Consistent with the results from the
hematopoietic progenitor cell colony-forming assays and PB analysis
presented above, these data demonstrate that the levels of
lineage-specific hematopoietic precursors in BM of mice are not
affected by the absence of catalytically active Fps.

View larger version (55K):
[in this window]
[in a new window]
|
FIG. 6.
Flow cytometry analysis. BM from wild-type (wt;
n = 7) animals or mice homozygous (hom; n = 6) or heterozygous (het; n = 7) for the
fpsK588R allele were isolated and subjected to
flow cytometry analysis. (A) Myeloid precursors were stained with PE
anti-Ly6G and FITC anti-CD11b, both of which are specific for cells of
the myeloid/monocytic lineage. (B) Erythroid precursors were stained
with the erythroid-specific MAb PE anti-TER119 and FITC anti-CD44,
which recognizes the majority of hematopoietic cells. (C) B cell
precursors were stained with PE anti-B220, which is B cell specific.
The percentage in the upper right hand corner of each quadrant
represents the average percentage of positively labeled cells out of
20,000 BM cells counted after lysis of erythrocytes.
|
|
Cytokine and LPS stimulation of cultured BMM.
To analyze any
perturbations in signaling pathways in these mice, we focused on BMM,
which normally express high levels of Fps and the cytokine receptors
with which Fps is thought to interact. BMM were cultured for
approximately 10 days, then starved in 0.5% FBS for 48 h,
followed by stimulation with the cytokines GM-CSF, IL-6, IL-3 (data not
shown), or LPS (Fig. 7). Immunoblotting
analysis following stimulation with GM-CSF revealed that Stat3 and
Stat5A did not undergo activating tyrosine phosphorylation to the same extent in BMM homozygous for the fpsK588R
mutation as in wild-type cells (Fig. 7A and B), suggesting that Fps is
somehow involved in regulating the tyrosine phosphorylation of these
two signaling proteins downstream from the GM-CSF receptor. A time
course of the phosphorylation of Stat3 following GM-CSF stimulation
revealed that the difference in phosphorylation status was greatest at
15 min after cytokine exposure (data not shown). Stat3 and Stat5A were
tyrosine phosphorylated to the same degree following IL-6 (Fig. 7A and
B) or IL-3 (data not shown) stimulation of wild-type and
fpsK588R cells, suggesting that Fps is not
involved in signaling from the IL-3 or IL-6 receptor in the same way as
it is in GM-CSF receptor signaling.

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 7.
Signaling in cultured fpsK588R
homozygous mutant BMM. BMM from wild-type (+/+) or homozygous mutant
( / ) mice were starved for 48 h in 0.5% FBS prior to
stimulation with either GM-CSF (30 ng/ml) or IL-6 (30 ng/ml). Cells
were exposed to each cytokine for 15 min at 37°C, scraped in 2× SDS
sample buffer, run out on an SDS-7.5% polyacrylamide gel, transferred
to Immobilon-P membrane, and then probed successively with the
indicated antibodies: (A) anti-pStat3 (top) followed by anti-Stat3
(bottom); or (B) anti-pStat5A/B (top) followed by anti-Stat5A (bottom).
Stat5B (90 to 92 kDa) is constitutively phosphorylated in these BMM
cultures, even under starvation conditions, whereas Stat5A (95 kDa) is
phosphorylated only following GM-CSF stimulation. (C) BMM were starved
for 48 h in 0.5% FBS prior to exposure to various doses of LPS
for 30 min at 37°C. Whole-cell lysates were run out on SDS-11%
polyacrylamide gels, transferred to Immobilon-P membrane, and then
probed with anti-Erk antibody (bottom) followed by anti-pErk antibody
(top).
|
|
As Jaks are presumed to be directly responsible for Stat
phosphorylation downstream of cytokine stimulation, we also checked
for
activation of Jak2 as the most likely candidate to be mediating
Stat3
and Stat5A phosphorylation following GM-CSF stimulation.
Interestingly,
Jak2 was tyrosine phosphorylated to a comparable
extent in wild-type
and homozygous mutant BMM following GM-CSF
stimulation (data not
shown). This suggested that Fps may act
somewhere downstream of Jak2 in
the activation of Stat3 and Stat5A,
possibly by phosphorylating a Stat
docking site on the GM-CSF
receptor

chain, or by phosphorylation of
Stat3 and Stat5A
directly.
We also analyzed the activation of Erk1 (p44) and Erk2 (p42) following
treatment of cultured BMM with LPS. Our results revealed
a
dose-dependent reduction in Erk1/2 activation, which was apparent
at an
LPS dose of 100 ng/ml (Fig.
7C). This difference in Erk
activation
between wild-type and homozygous mutant BMM was overcome
with a dose of
LPS an order of magnitude greater, suggesting that
compensatory
mechanisms were being activated at this higher LPS
dose, which
circumvented the block resulting from the catalytically
dead
Fps.
 |
DISCUSSION |
The results of this study demonstrate that Fps kinase activity is
not required for normal mouse development or the production of mature
hematopoietic cells. Interbreeding of heterozygous mutant mice produced
animals of all three genotypes in the expected Mendelian ratios,
showing that Fps kinase activity is not essential for any developmental
process in spite of its widely distributed expression pattern during
embryonic and fetal development (5, 22). Homozygous mutant
males and females were both fertile, producing normal litter sizes
either when bred to wild-type animals or when interbred, showing that
Fps activity is not essential for gametogenesis, fertilization, or any
other reproductive functions. Histological analysis of all major organs
and tissues has not revealed gross phenotypes in mutant animals (data
not shown). We have occasionally observed cellular hyperplasia in the
lung, which is reminiscent of the pathology seen in the GM-CSF or
GM-CSF receptor knockout mice (11, 53, 59); however, this
was not a consistent finding. We also saw elevated levels of peripheral
WBC and splenomegaly in some mutant animals, but these differences did
not reach statistical significance. BM-derived progenitor cells from
fps mutant mice and controls gave similar in vitro colony
growth responses to IL-3 and GM-CSF alone, or in combination with
Epo, as well as M-CSF (data not shown). We did note marginally
elevated numbers of CFU-GM colonies and larger variability in colony
numbers from the mutant animals in the presence of GM-CSF and IL-3.
Furthermore, CFU-GM from some homozygous mutant mice were substantially
larger and displayed greater cellular density. These observations
initially suggested increased numbers of myeloid progenitors in the BM
and perhaps an increased proliferative capacity of these mutant
progenitors. However, when these assays were repeated with larger
numbers of animals, the differences observed were not statistically
significant. The slight differences we observed in peripheral WBC,
spleen weights, and in vitro colony growth might have reflected
intermouse variation. Alternatively, these differences could have been
due to differences in immune status, although this seems unlikely, as
the cohorts of animals used in these experiments were housed together
in the same cages. LPS challenge did provoke greater increases in
peripheral WBC and splenomegaly in mutant mice; however, these
differences were not consistently observed and did not reach
statistical significance (data not shown). We also observed reduced
sensitivity to LPS-induced activation of Erk1 and Erk2 in mutant
macrophage cultures, which is again consistent with subtle defects in
immune response. Challenges with specific pathogens are being carried
out to pursue this line of investigation. Preliminary analysis of
phagocytosis also indicated that BMM from mutant animals were fully
capable of ingesting bacteria and mounting a typical oxidative burst
response (data not shown).
The fps proto-oncogene is most prominently expressed in the
myeloid lineage, and several observations have suggested an essential biological role for fps in the survival and differentiation
of myeloid progenitors (14, 64, 68). The evidence for a
molecular function of the Fps kinase in the regulation of myelopoiesis
comes largely from reports of its activation upon stimulation of
responsive cells with a number of cytokines which play prominent roles
in regulating the differentiation of hematopoietic progenitors along the myeloid and erythroid lineages (24, 25, 32, 40, 43) and
association with several members of the cytokine receptor superfamily,
including those for IL-3, GM-CSF, and Epo (4, 24, 25, 32,
51). Activation of these receptors leads to the tyrosine
phosphorylation and dimerization-induced activation of the Stats
(10). We therefore examined the tyrosine phosphorylation status of Stat3 and Stat5A in BM-derived monocytes from the
fps mutant mice after stimulation with the cytokines IL-3,
GM-CSF, and IL-6. All three cytokines induced activation of Stat3, and GM-CSF and IL-3 induced Stat5A activation in wild-type cells. In
contrast, tyrosine phosphorylation of Stat3 and Stat5A was dramatically
reduced in homozygous mutant cells after GM-CSF treatment. These
results strongly argue for an involvement of Fps in GM-CSF signaling,
which does not extend to signaling from IL-3 or IL-6 receptors. While
in humans, the receptors for IL-3, IL-5, and GM-CSF employ a common
-chain (26), the mouse genome appears to encode two
closely related
chains, one of which is specific to the IL-3
receptor (31), while the other appears to be parologous with
the human
chain (19). As activation of Stat3 and Stat5A appears to be compromised downstream of GM-CSF but not IL-3 in these
fps mutant mice, Fps may be required for signaling from the
common murine
chain, but it may not be necessary for signaling from
the IL-3-specific receptor. As this common murine
chain is employed
by the IL-5 receptor as well, it will be interesting to see if IL-5
signaling is also compromised in these animals. If this is the case, it
is possible that in humans, Fps plays an important role in signaling
downstream from IL-3, IL-5, and GM-CSF.
Ectopic expression studies have recently revealed an intrinsic ability
of Fps to phosphorylate and activate Stat3 (48) but not
Stat5A (38). It has also been suggested that GM-CSF
stimulation may induce a complex formation between Fps and Stat3
(50). Stat3 is also activated downstream from several other
cytokines, including IL-6, IL-11, oncostatin M, ciliary neurotrophic
factor, and leukemia inhibitory factor, all of which employ receptors
containing a common signaling chain called gp130. Indeed, Fps was shown
to associate with this common receptor subunit (43).
Although we have not looked extensively at signaling from all of these
cytokines, we did see normal IL-6-induced activation of Stat3 in BMM
from mutant fps mice; this suggests that Fps kinase activity
may not be required for Stat activation downstream of cytokines using the common gp130 receptor subunit.
Members of the Jak family of PTKs are acknowledged to play prominent
roles in transmitting signals from all members of the cytokine receptor
superfamily, and their role in Stat phosphorylation is well documented
(29, 38). The recently reported mouse knockout model of Jak2
clearly demonstrated an essential role for this kinase in signaling
from receptors from IL-3, IL-5, GM-CSF, Epo, and thrombopoietin
(49). In contrast, the involvement of Fps in signaling from
these cytokine receptors remains controversial. We found that
activation of Jak2 in response to GM-CSF, IL-3, and IL-6 was not
affected by loss of Fps kinase activity (data not shown). This suggests
that Fps kinase activity is not required for activation of Jak2. The
work reported here argues that Fps may indeed play an critical role in
signaling from the GM-CSF receptor and perhaps a redundant role in
signaling from other cytokine receptors. We cannot be certain if Fps is
directly responsible for tyrosine phosphorylation of Stat3 and Stat5A,
but this is certainly a possibility. This study provides the first in
vivo evidence for such a role for the Fps kinase. Other alternatives which must be considered include an indirect role, such as
phosphorylation of tyrosine residues on the GM-CSF receptor
chain,
which might act as recruitment sites for Stat3 or Stat5A, or a
kinase-dependent role of Fps as an adaptor protein involved in
recruitment of Stats to the activated receptor. In the absence of Fps
kinase activity, recruitment of Stat proteins to the receptor and
subsequent phosphorylation by Jak2 might be greatly compromised.
Normal numbers of mature myeloid cells in mice expressing only
catalytically inactive Fps indicates that either Fps kinase activity is
not involved in regulating myelopoiesis or its function is redundant
with that of other kinases. It is unlikely that Fps function is
independent of kinase activity; however, the generation and analysis of
Fps-null mice will be required to confirm this. Assuming Fps does play
a role in myelopoiesis, a possible explanation for the lack of a
substantial myeloid phenotype in mutant fps mice is
functional redundancy with some other kinase. The most likely candidate
is the widely expressed Fer kinase, which is the only other known
kinase with a structure closely related to that of Fps. Interestingly,
both Fps and Fer have been shown to oligomerize, and this is mediated
by the conserved coiled-coil motifs in their N-terminal domains
(8, 35, 52). Although this finding raises the possibility of
dominant-negative effects involving either homotypic (Fps-Fps) or
heterotypic (Fps-Fer) interactions, we have recently shown that Fps and
Fer do not interact (8). This would argue that kinase-dead
Fps is also unlikely to have a potent dominant-negative effect on Fer.
Furthermore, coexpression of wild-type and kinase-dead Fer at equimolar
levels did not result in any significant inhibition of Fer kinase
activity (8). In contrast, Fps kinase activity was shown to
be inhibited by either an N-terminal fragment of Fps or a full-length
kinase-dead mutant (52). However, these studies suggested
that substantial inhibition would not be seen at equimolar ratios.
This is substantiated by the normal GM-CSF-induced Stat3 and Stat5A
phosphorylation we observed in macrophages which are heterozygous
for the fpsK588R allele unpublished data.
The expression patterns of Fps and Fer are quite distinct. Fps is more
restricted, with relatively high levels seen in a limited subset of
cell types including myeloid cells, vascular endothelial cells,
chondrocytes, and some epithelial and neuronal cells (22). On the other hand Fer is very widely expressed (25, 39), and levels comparable to that of Fps in myeloid cells are seen in most
tissues. We have recently cloned the murine fer locus and have found that the exon structure is closely related to that of
mammalian fps (unpublished data). The close structural
relationship between fps and fer and their
encoded kinases suggests that they may engage in similar biological
functions. The observed association of Fps and Fer with a variety of
different cytokine and growth factor receptors suggests these kinases
may serve a general role in cell signaling and that fps may
have evolved more recently to provide this function in more specialized
cell types, such as those of the myeloid lineage or the vascular
endothelium. Interestingly, transgenic mice engineered to express an
activated fps allele displayed a vascular hyperplasia but no
apparent myeloid phenotype (20). Thus far we have not
detected substantial defects in the myeloid or vascular lineages in
mutant fps mice. We have recently targeted the murine
fer gene with a kinase-inactivating missense mutation
(8). Through the generation of compound mutant
fps and fer mice and performance of genetic
rescue experiments, we intend to establish whether these two related
kinases perform essential yet redundant functions in cytokine and
growth factor signaling.
 |
ACKNOWLEDGMENTS |
This work was supported by grant MT-11627 from the Medical
Research Council of Canada (MRC) and by the National Cancer Institutes of Canada with funds from the Canadian Cancer Society. Y.S. was supported by an Ontario Graduate Scholarship.
We are grateful to Robert Leggett and Karen Williams for technical
assistance, Sharon Sands for assistance with the hematological analysis, Derek Schulze for flow cytometry analysis, and Andrew Craig
and Waheed Sangrar for comments on the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Cancer Research
Laboratories, Departments of Pathology and Biochemistry, Department of
Biochemistry, Queen's University, Kingston, Ontario K7L 3N6, Canada.
Phone: (613) 533-2813. Fax: (613) 533-6830. E-mail:
greerp{at}post.queensu.ca.
 |
REFERENCES |
| 1.
|
Aardal, N. P., and O. D. Laerum.
1983.
Circadian variations in mouse bone marrow.
Exp. Hematol.
11:792-801[Medline].
|
| 2.
|
Alcalay, M.,
F. Antolini,
W. J. Van de Ven,
L. Lanfrancone,
F. Grignani, and P. G. Pelicci.
1990.
Characterization of human and mouse c-fes cDNA clones and identification of the 5' end of the gene.
Oncogene
5:267-275[Medline].
|
| 3.
|
Anderson, D. H., and P. M. Ismail.
1998.
v-Fps causes transformation of inducing tyrosine phosphorylation and activation of the PDGF receptor.
Oncogene
16:2321-2331[Medline].
|
| 4.
|
Brizzi, M. F.,
M. G. Aronica,
A. Rosso,
G. P. Bagnara,
Y. Yarden, and L. Pegoraro.
1996.
Granulocyte-macrophage colony-stimulating factor stimulates JAK2 signaling pathway and rapidly activates p93fes, STAT1 p91, and STAT3 p92 in polymorphonuclear leukocytes.
J. Biol. Chem.
271:3562-3567[Abstract/Free Full Text].
|
| 5.
|
Care, A.,
G. Mattia,
E. Montesoro,
I. Parolini,
G. Russo,
M. P. Colombo, and C. Peschle.
1994.
c-fes expression in ontogenetic development and hematopoietic differentiation.
Oncogene
9:739-747[Medline].
|
| 6.
|
Carmier, J. F., and J. Samarut.
1986.
Chicken myeloid stem cells infected by retroviruses carrying the v-fps oncogene do not require exogenous growth factors to differentiated in vitro.
Cell
44:159-165[Medline].
|
| 7.
|
Chan, A. C., and A. S. Shaw.
1996.
Regulation of antigen receptor signal transduction by protein tyrosine kinases.
Curr. Opin. Immunol.
8:394-401[Medline].
|
| 8.
|
Craig, A.,
R. Zirgibl,
L. A. Cole, and P. Greer.
1999.
Disruption of coiled-coil domains in Fer protein-tyrosine kinase abolishes trimerization but not kinase activation.
J. Biol. Chem.
274:19934-19943[Abstract/Free Full Text].
|
| 9.
|
Darnell, J. E., Jr.
1997.
STATs and gene regulation.
Science
277:1630-1635[Abstract/Free Full Text].
|
| 10.
|
da Silva, A. J.,
Z. Li,
C. de Vera,
E. Canto,
P. Findell, and C. E. Rudd.
1997.
Cloning of a novel T-cell protein FYB that binds FYN and SH2-domain-containing leukocyte protein 76 and modulates interleukin 2 production.
Proc. Natl. Acad. Sci. USA
94:7493-7498[Abstract/Free Full Text].
|
| 11.
|
Dranoff, G.,
A. D. Crawford,
M. Sadelain,
B. Ream,
A. Rashid,
R. T. Bronson,
G. R. Dickersin,
C. J. Bachurski,
E. L. Mark,
J. A. Whitsett, et al.
1994.
Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis.
Science
264:713-716[Abstract/Free Full Text].
|
| 12.
|
Ellis, C.,
M. Moran,
F. McCormick, and T. Pawson.
1990.
Phosphorylation of GAP and GAP-associated proteins by transforming and mitogenic tyrosine kinases.
Nature
343:377-381[Medline].
|
| 13.
|
Feldman, R. A.,
J. L. Gabrilove,
J. P. Tam,
M. A. S. Moore, and H. Hanafusa.
1985.
Specific expression of the human cellular fps/fes-encoded protein NCP92 in normal and leukemic myeloid cells.
Proc. Natl. Acad. Sci. USA
82:2379-2383[Abstract/Free Full Text].
|
| 14.
|
Ferrari, S.,
R. Manfredini,
E. Tagliafico,
A. Grande,
D. Barbieri,
R. Balestri,
M. Pizzanelli,
P. Zucchini,
G. Citro,
G. Zupi,
C. Franceschi, and U. Torelli.
1994.
Antipoptotic effect of c-fes protooncogene during granulocytic differentiation.
Leukemia
8(Suppl. 1):S91-S94.
|
| 15.
|
Ferrari, S.,
U. Torelli,
L. Selleri,
A. Donelli,
D. Venturelli,
L. Moretti, and G. Torelli.
1985.
Expression of human c-fes onc-gene occurs at detectable levels in myeloid but not in lymphoid cell populations.
Br. J. Haematol.
59:21-25[Medline].
|
| 16.
|
Fischman, K.,
J. C. Edman,
G. M. Shakleford,
J. A. Turner,
W. J. Rutter, and U. Nir.
1990.
A murine fer testis-specific transcript (ferT) encodes a truncated Fer protein.
Mol. Cell. Biol.
10:146-153[Abstract/Free Full Text].
|
| 17.
|
Fukui, Y., and H. Hanafusa.
1989.
Phosphatidylinositol kinase activity associated with viral p60src protein.
Mol. Cell. Biol.
9:1651-1658[Abstract/Free Full Text].
|
| 18.
|
Garcia, R.,
C. L. Yu,
A. Hudnall,
R. Catlett,
K. L. Nelson,
T. Smithgall,
D. J. Fujita,
S. P. Ethier, and R. Jove.
1997.
Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells.
Cell Growth Differ.
8:1267-1276[Abstract].
|
| 19.
|
Gorman, D.,
N. Itoh,
T. Kitamura,
J. Schreurs,
S. Yonehara,
I. Yahara,
K.-I. Arai, and A. Miyajima.
1990.
Cloning and expression of a gene encoding an interleukin 3 receptor-like protein: identification of another member of the cytokine receptor gene family.
Proc. Natl. Acad. Sci. USA
87:5459-5463[Abstract/Free Full Text].
|
| 20.
|
Greer, P.,
J. Haigh,
G. Mbamalu,
W. Khoo,
A. Bernstein, and T. Pawson.
1994.
The Fps/Fes protein-tyrosine kinase promotes angiogenesis in transgenic mice.
Mol. Cell. Biol.
14:6755-6763[Abstract/Free Full Text].
|
| 21.
|
Greer, P.,
V. Maltby,
J. Rossant,
A. Bernstein, and T. Pawson.
1990.
Myeloid expression of the human c-fps/fes proto-oncogene in transgenic mice.
Mol. Cell. Biol.
10:2521-2527[Abstract/Free Full Text].
|
| 22.
|
Haigh, J.,
J. McVeigh, and P. Greer.
1996.
The fps/fes tyrosine kinase is expressed in myeloid, vascular endothelial, epithelial, and neuronal cells and is localized in the trans-golgi network.
Cell Growth Differ.
7:931-944[Abstract].
|
| 23.
|
Hao, Q.-L.,
N. Heisterkamp, and J. Groffen.
1989.
Isolation and sequence analysis of a novel human tyrosine kinase.
Mol. Cell. Biol.
9:1587-1593[Abstract/Free Full Text].
|
| 24.
|
Hanazono, Y.,
S. Chiba,
K. Sasaki,
H. Mano,
A. Miyajima,
K. Arai,
Y. Yazaki, and H. Hirai.
1993.
c-fps/fes protein-tyrosine kinase is implicated in a signaling pathway triggered by granulocyte-macrophage colony stimulating factor and interleukin-3.
EMBO J.
12:1641-1646[Medline].
|
| 25.
|
Hanazono, Y.,
S. Chiba,
K. Sasaki,
H. Mano,
Y. Yazaki, and H. Hirai.
1993.
Erythropoietin induces tyrosine phosphorylation and kinase activity of the c-fps/fes proto-oncogene product in human erythropoietin-responsive cells.
Blood
81:3193-3196[Abstract/Free Full Text].
|
| 26.
|
Hayashida, K.,
T. Kitamura,
D. M. Gorman,
K. Arai,
T. Yokota, and A. Miyajima.
1990.
Molecular cloning of a second subunit of the receptor for human granulocyte-macrophage colony-stimulating factor (GM-CSF): reconstitution of a high-affinity GM-CSF receptor.
Proc. Natl. Acad. Sci. USA
87:9655-9659[Abstract/Free Full Text].
|
| 27.
|
Hjermstad, S. J.,
S. D. Briggs, and T. E. Smithgall.
1993.
Phosphorylation of the ras GTPase-activating protein (GAP) by the p93c-fes protein-tyrosine kinase in vitro and formation of GAP-fes complexes via an SH2 domain-dependent mechanism.
Biochemistry
32:10519-10525[Medline].
|
| 28.
|
Hjermstad, S. J.,
K. L. Peters,
S. D. Briggs,
R. I. Glazer, and T. E. Smithgall.
1993.
Regulation of the human c-fes protein tyrosine kinase (p93c-fes) by its src homology 2 domain and major autophosphorylation site (Tyr-713).
Oncogene
8:2283-92[Medline].
|
| 29.
|
Ihle, J. N.
1995.
Cytokine receptor signalling.
Nature
377:591-594[Medline].
|
| 30.
|
Ihle, J. N., and I. M. Kerr.
1995.
Jaks and Stats in signaling by the cytokine receptor superfamily.
Trends Genet.
11:69-74[Medline].
|
| 31.
|
Itoh, N.,
S. Yonehara,
J. Schreurs,
D. M. Gorman,
K. Maruyama,
A. Ishii,
I. Yahara,
K. Arai, and A. Miyajima.
1990.
Cloning of an interleukin-3 receptor gene: a member of a distinct receptor gene family.
Science
247:324-327[Abstract/Free Full Text].
|
| 32.
|
Izuhara, K.,
R. A. Feldman,
P. Greer, and N. Harada.
1994.
Interaction of the c-fes proto-oncogene product with the interleukin-4 receptor.
J. Biol. Chem.
269:18623-18629[Abstract/Free Full Text].
|
| 33.
|
Jucker, M.,
K. McKenna,
A. J. da Silva,
C. E. Rudd, and R. A. Feldman.
1997.
The Fes protein-tyrosine kinase phosphorylates a subset of macrophage proteins that are involved in cell adhesion and cell-cell signaling.
J. Biol. Chem.
272:2104-2109[Abstract/Free Full Text].
|
| 34.
|
Kahn, P.,
B. Adkins,
H. Beug, and T. Graf.
1984.
src- and fps-containing avian sarcoma viruses transform chicken erythroid cells.
Proc. Natl. Acad. Sci. USA
81:7122-6[Abstract/Free Full Text].
|
| 35.
|
Kim, L., and T. W. Wong.
1995.
The cytoplasmic tyrosine kinase Fer is associated with the catenin-like substrate pp120 and is activated by growth factors.
Mol. Cell. Biol.
15:4553-4561[Abstract].
|
| 36.
|
Koch, C. A.,
M. Moran,
I. Sadowski, and T. Pawson.
1989.
The common Src homology region 2 domain of cytoplasmic signaling proteins is a positive effector of v-Fps tyrosine kinase function.
Mol. Cell. Biol.
9:4131-4140[Abstract/Free Full Text].
|
| 37.
|
Kurata, W. E., and A. F. Lau.
1994.
p130gag-fps disrupts gap junctional communication and induces phosphorylation of connexin43 in a manner similar to that of pp60v-src.
Oncogene
9:329-335[Medline].
|
| 38.
|
Leonard, W. J., and J. J. O'Shea.
1998.
Jaks and Stats: biological implications.
Annu. Rev. Immunol.
16:293-322[Medline].
|
| 39.
|
Letwin, K.,
S.-P. Yee, and T. Pawson.
1988.
Novel protein-tyrosine kinase cDNAs related to fps/fes and eph cloned using anti-phosphotyrosine antibody.
Oncogene
3:621-627[Medline].
|
| 40.
|
Linnekin, D.,
S. M. Mou,
P. Greer,
D. L. Longo, and D. K. Ferris.
1995.
Phosphorylation of a Fes-related protein in response to granulocyte-macrophage colony stimulating factor.
J. Biol. Chem.
270:4950-4954[Abstract/Free Full Text].
|
| 41.
|
MacDonald, I.,
J. Levy, and T. Pawson.
1985.
Expression of the mammalian c-fes protein in hematopoietic cells and identification of a distinct fes-related protein.
Mol. Cell. Biol.
5:2543-2551[Abstract/Free Full Text].
|
| 42.
|
Maru, Y.,
K. L. Peters,
D. E. Afar,
M. Shibuya,
O. N. Witte, and T. E. Smithgall.
1995.
Tyrosine phosphorylation of BCR by FPS/FES protein-tyrosine kinases induces association of BCR with GRB-2/SOS.
Mol. Cell. Biol.
15:835-842[Abstract].
|
| 43.
|
Matsuda, T.,
T. Fukada,
M. Takahashi-Tezuka,
Y. Okuyama,
Y. Fujitani,
Y. Hanazono,
H. Hirai, and T. Hirano.
1995.
Activation of Fes tyrosine kinase by gp130, an interleukin-6 family cytokine signal transducer, and their association.
J. Biol. Chem.
270:11037-11039[Abstract/Free Full Text].
|
| 44.
|
McGlade, J.,
A. Cheng,
G. Pelicci,
P. G. Pelicci, and T. Pawson.
1992.
Shc proteins are phosphorylated and regulated by the v-Src and v-Fps protein-tyrosine kinases.
Proc. Natl. Acad. Sci. USA
89:8869-8873[Abstract/Free Full Text].
|
| 45.
|
Meckling-Gill, K. A.,
S. P. Yee,
J. W. Schrader, and T. Pawson.
1992.
A retrovirus encoding the v-fps protein-tyrosine kinase induces factor-independent growth and tumorigenicity in FDC-P1 cells.
Biochim. Biophys. Acta
1137:65-72[Medline].
|
| 46.
|
Moran, M. F.,
P. Polakis,
F. McCormick,
T. Pawson, and C. Ellis.
1991.
Protein-tyrosine kinases regulate the phosphorylation, protein interactions, and subcellular distribution of p21ras GTPase-activating protein.
Mol. Cell. Biol.
11:1804-1812[Abstract/Free Full Text].
|
| 47.
|
Nagy, A.,
J. Rossant,
R. Nagy,
W. Abramow-Newerly, and J. C. Roder.
1993.
Derivation of completely cell culture-derived mice from early-passage embryonic stem cells.
Proc. Natl. Acad. Sci. USA
90:8424-8428[Abstract/Free Full Text].
|
| 48.
|
Nelson, K. L.,
J. A. Rogers,
T. L. Bowman,
R. Jove, and T. Smithgall.
1998.
Activation of Stat3 by the c-Fes protein-tyrosine kinase.
J. Biol. Chem.
273:7072-7077[Abstract/Free Full Text].
|
| 49.
|
Parganas, E.,
D. Wang,
D. Stravopodis,
D. J. Topham,
J. C. Marine,
S. Teglund,
E. F. Vanin,
S. Bodner,
O. R. Colamonici,
J. M. van Deursen,
G. Grosveld, and J. N. Ihle.
1998.
Jak2 is essential for signaling through a variety of cytokine receptors.
Cell
93:385-395[Medline].
|
| 50.
|
Park, W. Y.,
J. H. Ahn,
R. A. Feldman, and J. S. Seo.
1998.
c-Fes tyrosine kinase binds to and activates STAT3 after granulocyte-macrophage colony-stimulating factor stimulation.
Cancer Lett.
129:29-37[Medline].
|
| 51.
|
Rao, P., and R. A. Mufson.
1995.
A membrane proximal domain of the human interleukin-3 receptor beta c subunit that signals DNA synthesis in NIH 3T3 cells specifically binds a complex of Src and Janus family tyrosine kinases and phosphatidylinositol 3-kinase.
J. Biol. Chem.
270:6886-6893[Abstract/Free Full Text].
|
| 52.
|
Read, R. D.,
J. M. Lionberger, and T. E. Smithgall.
1997.
Oligomerization of the Fes tyrosine kinase.
J. Biol. Chem.
272:18498-18503[Abstract/Free Full Text].
|
| 53.
|
Robb, L.,
C. C. Drinkwater,
D. Metcalf,
R. Li,
F. Kontgen,
N. A. Nicola, and C. G. Begley.
1995.
Hematopoietic and lung abnormalities in mice with a null mutation of the common beta subunit of the receptors for granulocyte-macrophage colony-stimulating factor and interleukins 3 and 5.
Proc. Natl. Acad. Sci. USA
92:9565-9569[Abstract/Free Full Text].
|
| 54.
|
Robinson, R. C.,
L. M. Grey,
D. Staunton,
H. Vankelecom,
A. B. Vernallis,
J.-F. Moreau,
D. I. Stuart,
J. K. Heath, and E. Y. Jones.
1994.
The crystal structure and biological function of leukemia inhibitory factor: implications for receptor binding.
Cell
77:1101-1116[Medline].
|
| 55.
|
Roebroek, A. J. M.,
J. A. Schalken,
J. S. Verbeek,
A. M. W. Van den Ouweland,
C. Onnekink,
H. P. J. Bloemers, and W. J. M. Van de Ven.
1985.
The structure of the human c-fps/fes proto-oncogene.
EMBO J.
4:2897-2903[Medline].
|
| 56.
|
Sadowski, I.,
T. Pawson, and A. Lagarde.
1988.
v-fps protein-tyrosine kinase coordinately enhances the malignancy and growth factor responsiveness of pre-neoplastic lung fibroblasts.
Oncogene
2:241-247[Medline].
|
| 57.
|
Sanderson, J. H., and C. E. Phillips.
1981.
An atlas of laboratory animal haematology.
Clarendon Press, Oxford, England.
|
| 58.
|
Songyang, Z.,
S. E. Shoelson,
J. McGlade,
P. Olivier,
T. Pawson,
X. R. Bustelo,
M. Barbacid,
H. Sabe,
H. Hanafusa,
T. Yi,
R. Ren,
D. Baltimore,
S. Ratnofsky,
R. A. Feldman, and L. C. Cantley.
1994.
Specific motifs recognized by the SH2 domains of Csk, 3BP2, Fps/Fes, GRB-2, HCP, SHC, Syk, and Vav.
Mol. Cell. Biol.
14:2777-2785[Abstract/Free Full Text].
|
| 59.
|
Stanley, E.,
G. J. Lieschke,
D. Grail,
D. Metcalf,
G. Hodgson,
J. A. Gall,
D. W. Maher,
J. Cebon,
V. Sinickas, and A. R. Dunn.
1994.
Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology.
Proc. Natl. Acad. Sci. USA
91:5592-5596[Abstract/Free Full Text].
|
| 60.
|
Tushinski, R. J.,
I. T. Oliver,
L. J. Guilbert,
P. W. Tynan,
J. R. Warner, and E. R. Stanley.
1982.
Survival of mononuclear phagocytes depends on a lineage-specific growth factor that the differentiated cells selectively destroy.
Cell
28:71-81[Medline].
|
| 61.
|
Tybulewicz, V. L. J.,
C. E. Crawford,
P. K. Jackson,
R. T. Bronson, and R. C. Mulligan.
1991.
Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene.
Cell
65:1153-1163[Medline].
|
| 62.
|
Wilks, A. F., and R. R. Kurban.
1988.
Isolation and structural analysis of murine c-fes cDNA clones.
Oncogene
3:289-294[Medline].
|
| 63.
|
Wurst, W., and A. L. Joyner.
1993.
Production of targeted embryonic stem cell clones, p. 33-62.
In
A. L. Joyner (ed.), Gene targeting, 1st ed. IRL Press, Oxford, England.
|
| 64.
|
Yates, K. E.,
G. M. Crooks, and J. C. Gasson.
1996.
Analysis of Fes kinase activity in myeloid cell growth and differentiation.
Stem Cells
14:714-724[Medline].
|
| 65.
|
Yates, K. E., and J. C. Gasson.
1996.
Role of c-Fes in normal and neoplastic hematopoiesis.
Stem Cells
14:117-123[Medline].
|
| 66.
|
Yee, S. P.,
D. Mock,
P. Greer,
V. Maltby,
J. Rossant,
A. Bernstein, and T. Pawson.
1989.
Lymphoid and mesenchymal tumors in transgenic mice expressing the v-Fps protein-tyrosine kinase.
Mol. Cell. Biol.
9:5491-5499[Abstract/Free Full Text].
|
| 67.
|
Yee, S. P.,
D. Mock,
V. Maltby,
M. Silver,
J. Rossant,
A. Bernstein, and T. Pawson.
1989.
Cardiac and neurological abnormalities in v-fps transgenic mice.
Proc. Natl. Acad. Sci. USA
86:5873-5877[Abstract/Free Full Text].
|
| 68.
|
Yu, G.,
T. E. Smithgall, and R. I. Glazer.
1989.
K562 leukemia cells transfected with the human c-fes gene acquire the ability to undergo myeloid differentiation.
J. Biol. Chem.
264:10276-10281[Abstract/Free Full Text].
|
Molecular and Cellular Biology, November 1999, p. 7436-7446, Vol. 19, No. 11
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Voisset, E., Lopez, S., Dubreuil, P., De Sepulveda, P.
(2007). The tyrosine kinase FES is an essential effector of KITD816V proliferation signal. Blood
110: 2593-2599
[Abstract]
[Full Text]
-
Parsons, S. A., Greer, P. A.
(2006). The Fps/Fes kinase regulates the inflammatory response to endotoxin through down-regulation of TLR4, NF-{kappa}B activation, and TNF-{alpha} secretion in macrophages. J. Leukoc. Biol.
80: 1522-1528
[Abstract]
[Full Text]
-
Udell, C. M., Samayawardhena, L. A., Kawakami, Y., Kawakami, T., Craig, A. W. B.
(2006). Fer and Fps/Fes Participate in a Lyn-dependent Pathway from Fc{epsilon}RI to Platelet-Endothelial Cell Adhesion Molecule 1 to Limit Mast Cell Activation. J. Biol. Chem.
281: 20949-20957
[Abstract]
[Full Text]
-
Sangrar, W., Zirgnibl, R. A., Gao, Y., Muller, W. J., Jia, Z., Greer, P. A.
(2005). An Identity Crisis for fps/fes: Oncogene or Tumor Suppressor?. Cancer Res.
65: 3518-3522
[Abstract]
[Full Text]
-
Craig, A. W. B., Greer, P. A.
(2002). Fer Kinase Is Required for Sustained p38 Kinase Activation and Maximal Chemotaxis of Activated Mast Cells. Mol. Cell. Biol.
22: 6363-6374
[Abstract]
[Full Text]
-
McCafferty, D.-M., Craig, A. W. B., Senis, Y. A., Greer, P. A.
(2002). Absence of Fer Protein-Tyrosine Kinase Exacerbates Leukocyte Recruitment in Response to Endotoxin. J. Immunol.
168: 4930-4935
[Abstract]
[Full Text]
-
Zirngibl, R. A., Senis, Y., Greer, P. A.
(2002). Enhanced Endotoxin Sensitivity in Fps/Fes-Null Mice with Minimal Defects in Hematopoietic Homeostasis. Mol. Cell. Biol.
22: 2472-2486
[Abstract]
[Full Text]
-
Kim, J., Feldman, R. A.
(2002). Activated Fes Protein Tyrosine Kinase Induces Terminal Macrophage Differentiation of Myeloid Progenitors (U937 Cells) and Activation of the Transcription Factor PU.1. Mol. Cell. Biol.
22: 1903-1918
[Abstract]
[Full Text]
-
Cheng, H. Y., Schiavone, A. P., Smithgall, T. E.
(2001). A Point Mutation in the N-Terminal Coiled-Coil Domain Releases c-Fes Tyrosine Kinase Activity and Survival Signaling in Myeloid Leukemia Cells. Mol. Cell. Biol.
21: 6170-6180
[Abstract]
[Full Text]
-
Keller, P., Payne, J. L., Tremml, G., Greer, P. A., Gaboli, M., Pandolfi, P. P., Bessler, M.
(2001). Fes-Cre Targets Phosphatidylinositol Glycan Class a (Piga) Inactivation to Hematopoietic Stem Cells in the Bone Marrow. JEM
194: 581-590
[Abstract]
[Full Text]
-
Craig, A. W. B., Zirngibl, R., Williams, K., Cole, L.-A., Greer, P. A.
(2001). Mice Devoid of Fer Protein-Tyrosine Kinase Activity Are Viable and Fertile but Display Reduced Cortactin Phosphorylation. Mol. Cell. Biol.
21: 603-613
[Abstract]
[Full Text]
-
Rogers, J. A., Cheng, H. Y., Smithgall, T. E.
(2000). Src Homology 2 Domain Substitution Modulates the Kinase and Transforming Activities of the Fes Protein-Tyrosine Kinase. Cell Growth Differ.
11: 581-592
[Abstract]
[Full Text]
-
Heydemann, A., Warming, S., Clendenin, C., Sigrist, K., Hjorth, J. P., Simon, M. C.
(2000). A minimal c-fes cassette directs myeloid-specific expression in transgenic mice. Blood
96: 3040-3048
[Abstract]
[Full Text]